The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical, neuroimaging, epidemiological, and clinical literature without systematic methodology
PubMed 42289917 · doi:10.1111/bcpt.70264
What was done
This narrative review synthesized translational evidence on iatrogenic impulsive-compulsive behaviour (ICB) caused by dopaminergic medications used for disorders such as Parkinson's disease and restless legs syndrome. The authors compiled findings across epidemiological, clinical, neuroimaging, and animal model studies to examine drug-specific risks, neural circuitry involving the striatum and prefrontal cortex, and clinical management approaches.
What was found
The abstract provides qualitative conclusions and reports no numerical data, effect sizes, or participant numbers. High D2/3-selective dopamine agonists were most strongly and dose-dependently associated with ICB. Evidence regarding extended-release formulations or multi-drug combinations was noted as less clear. Intervention studies support tapering or substituting dopamine agonists to reduce ICB, with no specific pharmacotherapies identified as efficacious for treating ICB directly.
Why it matters
It consolidates translational evidence on a major iatrogenic behavioural side effect of dopamine agonists, underscoring that dose reduction or drug replacement remains the primary management strategy.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic synthesis. The abstract provides no quantitative metrics or study counts. Most evidence is derived from Parkinson's disease, limiting generalizability to other indications, and the efficacy of specific pharmacotherapies for ICB remains unproven.